Hydrocephalus News and Research

RSS

Hydrocephalus is an abnormal buildup of cerebrospinal fluid in the ventricles of the brain.

Afinitor tablets decrease size of SEGA associated with tuberous sclerosis

The New England Journal of Medicine (NEJM) today published a study that found patients taking Afinitor (everolimus) tablets experienced a decrease in the size of their subependymal giant cell astrocytoma (SEGA), a benign brain tumor associated with tuberous sclerosis (TS).

4 Nov 2010

Integra LifeSciences signs multi-year contract with The Broadlane Group

Integra LifeSciences Holdings Corporation announced today that it has signed a multi-year contract with The Broadlane Group to provide dural repair, neuro trauma (neuro critical care), and hydrocephalus products and accessories to its client hospitals.

1 Nov 2010

New Integra Flow Regulating Valve, Mini featured at 2010 neurological surgeons congress

Integra LifeSciences Holdings Corp will feature the new Integra™ Flow Regulating Valve, Mini, a smaller version of the Integra NPH™ Low Flow Valve, at the 2010 Congress of Neurological Surgeons Annual Meeting in San Francisco, California, October 16-21, 2010. The Integra™ Flow Regulating Valve, Mini is Integra's newest implantable shunt valve used in the management of hydrocephalus and was designed with a lower profile than the Integra NPH™ valve to accommodate various patient populations, particularly patients with thin, fragile skin.

19 Oct 2010

COE on Brain Aging at NYU Langone establishes Lewy Body Disease Center

The Center of Excellence (COE) on Brain Aging at NYU Langone Medical Center has established a specialty center for the diagnosis and treatment of Lewy Body Disease, a multi-system disease involving disturbances of cognition, behavior, sleep and autonomic function. Lewy Body Disease, or LBD, affects an estimated 1.3 million individuals in the United States and is widely misdiagnosed because LBD symptoms closely resemble those of other more commonly known diseases such as Alzheimer's and Parkinson's disease.

30 Sep 2010

Johnson & Johnson acquires Marus Endovascular

Johnson & Johnson today announced that it has completed the acquisition of Micrus Endovascular, a global developer and manufacturer of minimally invasive devices for hemorrhagic and ischemic stroke. Johnson & Johnson announced its agreement to acquire Micrus on July 12, 2010.

28 Sep 2010

Researchers create device to find ways to improve commonly used treatment for 'water on the brain'

Van Andel Research Institute (VARI) scientists participated in a study with researchers from the University of Utah that could help find ways to improve shunt systems used to treat the neurological disorder hydrocephalus, or "water on the brain," the leading cause of brain surgery for children in the United States. Researchers studied the shunt systems under a variety of conditions by creating a bioreactor that mimics the environment inside patients.

24 Sep 2010

NJIT researchers awarded 15 new U.S. patents for research programs

NJIT researchers were awarded 15 new U.S. patents this past year, increasing the total number of issued patents for NJIT to 97. More than 150 applications are in process. With projected research expenditures greater than $90 million for 2010-11, NJIT ranks as a leader in size and growth of research programs among technological universities. The patents were awarded from July 1, 2009-June 30, 2010. Specifics follow.

24 Aug 2010

Professor develops sensor to better regulate fluid flow in hydrocephalus

Hydrocephalus, or "water on the brain" as it is often called, is a condition that is diagnosed in tens of thousands in the U.S. every year, causing symptoms from mild gait problems to life-threatening seizures.

16 Jul 2010

Johnson & Johnson to acquire Micrus Endovascular

Johnson & Johnson and Micrus Endovascular Corporation, a global developer and manufacturer of minimally invasive devices to address hemorrhagic and ischemic stroke, today announced a definitive agreement whereby Micrus Endovascular will be acquired in a cash for stock exchange.

12 Jul 2010

Researchers to study interventional endovascular therapy on symptoms and progression of MS

Buffalo medical researchers led by a team from the University at Buffalo Department of Neurosurgery, will embark on a landmark prospective randomized double-blinded study to test the safety and efficacy of interventional endovascular therapy -- dubbed "liberation treatment" -- on the symptoms and progression of Multiple Sclerosis.

1 Jul 2010

Novartis' Afinitor decreases size of SEGAs associated with tuberous sclerosis

Novartis Pharmaceuticals Corporation announced today that results from a Phase II study show Afinitor® (everolimus) tablets is the first medication in a clinical trial to decrease the size of subependymal giant cell astrocytomas (SEGAs), benign brain tumors associated with tuberous sclerosis (TS). In this study of 28 patients presented today at the 46th American Society of Clinical Oncology (ASCO) annual meeting in Chicago, 75% of patients experienced a reduction of 30% or greater in the size of their brain tumors from baseline to six months (p<0.001).

7 Jun 2010

Research analyzes clinical connection of NPH to AD

Normal Pressure Hydrocephalus is a neurological condition which typically affects adults ages 55 and older. This condition was first described in the 1960s as a triad of gait disturbance, dementia, and bladder incontinence. The ventricles of the brain appear enlarged although the cerebrospinal fluid pressure remains normal.

5 May 2010

President of Tanzania emphasizes on health care in Global Health Grand Rounds lecture

President Jakaya Kikwete of the United Republic of Tanzania spoke at Weill Cornell Medical College today. In his Global Health Grand Rounds lecture, President Kikwete discussed the most significant challenges facing Tanzania, with a particular focus on health care and the advances made during his first term.

17 Apr 2010

Gene implicated in JSRDs: UCD research team publishes new information

Researchers in University College Dublin (UCD) led by Conway Fellow, Dr Oliver Blacque have revealed new information about a gene implicated in Joubert syndrome and related cerebellar disorders (JSRDs) that are characterised by blindness, bone abnormalities, cystic kidneys, developmental delay and loss of muscle tone and control. The findings from this research, which is funded by Science Foundation Ireland, have been published today in a leading science journal, Journal of Cell Biology.

22 Mar 2010

Likvor receives first order for Likvor CELDA system from Aalborg Hospital, North Denmark Region

LinkMed’s portfolio company Likvor has received its first order for the Likvor CELDA™ system from a customer outside Sweden. The order comes from Aalborg Hospital which is the largest hospital in the North Denmark Region.

8 Mar 2010

Pioneering 'brain-washing' treatment helps reduce disability in babies with haemorrhage

The research, led by Andrew Whitelaw, Professor of Neonatal Medicine at the University of Bristol, and Ian Pople, paediatric neurosurgeon at North Bristol NHS Trust, has shown that, after a haemorrhage, the fluid inside the ventricles contains substances potentially toxic to the immature brain.

8 Mar 2010

Special issue reviews current state of science in fetal therapy

Repairing birth defects in the womb. Inserting a tiny laser into the mother's uterus to seal off an abnormal blood flow and save fetal twins. Advancing the science that may allow doctors to deliver cells or DNA to treat sickle cell anemia and other genetic diseases before birth.

17 Feb 2010

Olfactory dysfunction may serve as an early diagnostic tool for Alzheimer's disease

A study published in the January 13, 2010 issue of the Journal of Neuroscience links a loss of smell function in Alzheimer's disease (AD) model animals with amyloid β (protein) accumulation in the brain, a distinguishing hallmark of Alzheimer's disease. Research conducted by NYU Langone Medical Center suggests that olfactory dysfunction, a common symptom of AD, may serve as an early diagnostic tool for the disease.

13 Jan 2010

LinkMed’s portfolio company Likvor receives new order for Likvor CELDA

LinkMed’s portfolio company Likvor has received a new order for Likvor CELDA™ ,this time from Sahlgrenska University Hospital in Gothenburg. With Likvor CELDA™ the clinical will be able to dynamic measure the most important parameters concerning the patients’ cerebrospinal fluid including pressure and flow in a controlled and safe process.

9 Jan 2010

Hydrocephalus Association awards stimulus grants for research initiative

The Hydrocephalus Association has announced research grants to scientists at five medical centers, in a new initiative to address the shortfall in progress in the treatment of hydrocephalus, a condition affecting one million Americans.

17 Dec 2009